This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Isaac Schiff, MD; Dan Tulchinsky, MD; Daniel Cramer, MD; Kenneth J. Ryan, MD

JAMA. 1980;244(13):1443-1445.

Abstract
A double-blind crossover study was designed to compare the effects of placebo and medroxyprogesterone acetate, 20 mg, on vasomotor flushes and blood hormones in 27 postmenopausal women. In women receiving placebo, vasomotor flushes were decreased by 25.9% during the last four weeks of treatment compared with baseline, and a further decrease of 34.5% was achieved by the last four weeks after patients were given medroxyprogesterone. In women who initially took medroxyprogesterone, there was a 73.9% decline by the last four weeks in the number of vasomotor flushes. However, when these women were given placebo, an immediate worsening of their symptoms occurred. The drug produced a decline of 27% and 29% in serum levels of follicle-stimulating hormone and luteinizing hormone, respectively, while the serum prolactin level rose slightly. Thus, medroxyprogesterone can be used to treat the vasomotor flushes of postmenopausal women when estrogen use is undesirable.

(JAMA 244:1443-1445, 1980)

Author Affiliations
From the Menopausal Unit, Boston Hospital for Women, and Harvard Medical School, Boston.

Footnotes
Reprint requests to Boston Hospital for Women, 221 Longwood Ave, Boston, MA 02115 (Dr Schiff).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women
Benster et al.
Menopause Int 2009;15:63-69.
ABSTRACT | FULL TEXT  

Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626
Goodwin et al.
JCO 2008;26:1650-1656.
ABSTRACT | FULL TEXT  

Management of Menopausal Symptoms
Grady
NEJM 2006;355:2338-2347.
FULL TEXT  

Symptoms and treatment in cancer therapy-induced early menopause.
Boekhout et al.
The Oncologist 2006;11:641-654.
ABSTRACT | FULL TEXT  

Nonestrogen Treatment Modalities for Vasomotor Symptoms Associated with Menopause
Fugate and Church
The Annals of Pharmacotherapy 2004;38:1482-1499.
ABSTRACT | FULL TEXT  

Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study
Bertelli et al.
Ann Oncol 2002;13:883-888.
ABSTRACT | FULL TEXT  

Cooling Off Hot Flashes
Stearns and Hayes
JCO 2002;20:1436-1438.
FULL TEXT  

Extracts from "Clinical Evidence": Menopausal symptoms
Rymer and Morris
BMJ 2000;321:1516-1519.
ABSTRACT | FULL TEXT  

Perimenopause: The Complex Endocrinology of the Menopausal Transition
Prior
Endocr. Rev. 1998;19:397-428.
ABSTRACT | FULL TEXT  

Megestrol Acetate for the Prevention of Hot Flashes
Loprinzi et al.
NEJM 1994;331:347-352.
ABSTRACT | FULL TEXT  

Estrogen Withdrawal Syndrome
Yen
JAMA 1986;255:1614-1615.
ABSTRACT  

Menopausal Endocrinology and Management
Korenman
Arch Intern Med 1982;142:1131-1136.
ABSTRACT  

Flushing Reactions: Consequences and Mechanisms
WILKIN
ANN INTERN MED 1981;95:468-476.
ABSTRACT